Ticker Details
Editas Medicine, Inc. Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes.
IPO Date:	February 3, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$477.63M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.73 | 3.79%
Avg Daily Range (30 D):	$0.09 | 3.24%
Avg Daily Range (90 D):	$0.12 | 4.02%

Institutional Daily Volume
Avg Daily Volume:	1.35M
Avg Daily Volume (30 D):	1.84M
Avg Daily Volume (90 D):	2.13M

Trade Size
Avg Trade Size (Sh.):	116
Avg Trade Size (Sh.) (30 D):	162
Avg Trade Size (Sh.) (90 D):	177

Institutional Trades
Total Institutional Trades:	3,843
Avg Institutional Trade:	$2M
Avg Institutional Trade (30 D):	$.71M
Avg Institutional Trade (90 D):	$1.18M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.77M
Avg Closing Trade (30 D):	$.74M
Avg Closing Trade (90 D):	$1.29M
Avg Closing Volume:	162.87K

News

Jul 14, 2026 @ 3:00 PM Lyora Therapeutics Launches With Seed Funding to P... Source: Unknown

Jul 3, 2026 @ 8:44 AM Gene Editing Therapeutics: Transforming Biopharmac... Source: Researchandmarkets.Com

Jul 3, 2026 @ 8:41 AM Global CRISPR-Based Drug Development Platforms Mar... Source: Researchandmarkets.Com

May 31, 2026 @ 4:11 PM CRISPR Therapeutics vs. Editas Medicine: Which Gen... Source: Robert Izquierdo

Apr 15, 2026 @ 6:00 PM Neutrolis Appoints Caren Deardorf as Chief Busines... Source: Not Specified

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.68	$-.15	$-.26
Diluted EPS	$-.68	$-.15	$-.26
Revenue	$47.01M	$11.89M	$2.83M
Gross Profit
Net Income / Loss	$-73.95M	$-18.23M	$-24.98M
Operating Income / Loss	$-75.86M	$-18.55M	$-25M
Cost of Revenue
Net Cash Flow	$42.07M	$35.17M	$M
PE Ratio